Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
Open Access
- 5 December 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 96 (1), 143-150
- https://doi.org/10.1038/sj.bjc.6603501
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccinationVaccine, 2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysisThe Lancet, 2005
- Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Carcinogenicity of human papillomavirusesThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Evaluating Human Papillomavirus Vaccination ProgramsEmerging Infectious Diseases, 2004
- Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer.JNCI Journal of the National Cancer Institute, 1999
- Natural History of Dysplasia of the Uterine CervixJNCI Journal of the National Cancer Institute, 1999